April 1, 2026
In drug development, brilliant science alone doesn’t secure regulatory approval—or commercial success. Technical risks related to Chemistry, Manufacturing, and Controls (CMC), regulatory pathways, and manufacturing scalability are often the silent killers of otherwise promising programs. For investors evaluating biotech opportunities, understanding how technical risk evolves from concept to approval is critical to making informed, strategic […]
